CS248086B1 - Method of apyrogenic treatment of animal alumin for veterinary intravein application - Google Patents
Method of apyrogenic treatment of animal alumin for veterinary intravein application Download PDFInfo
- Publication number
- CS248086B1 CS248086B1 CS805284A CS805284A CS248086B1 CS 248086 B1 CS248086 B1 CS 248086B1 CS 805284 A CS805284 A CS 805284A CS 805284 A CS805284 A CS 805284A CS 248086 B1 CS248086 B1 CS 248086B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- albumin
- solution
- animal
- veterinary
- pyrogen
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 9
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 title 1
- 108010088751 Albumins Proteins 0.000 claims abstract description 26
- 102000009027 Albumins Human genes 0.000 claims abstract description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 239000010425 asbestos Substances 0.000 claims description 5
- 229910052895 riebeckite Inorganic materials 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 230000001698 pyrogenic effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001047 pyretic effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011082 depyrogenation Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Riešenie možno použiť v imunologicko- -biologickej výrobě veterinárnych liečebných prípravkov. Očelom nového riešenie je podstatné zvýšenie kvalitatívnych parametrov doteraz vyrábaného zvieracieho albuminu, zvýšenie jeho liečebného efektu a rozšírenie indikácie. Zvýšenie účinku sa dosahuje tým, že komerčně vyrábaný zvierací albumin, ktorý vykazuje poměrně vysoké pyretické reakcie sa rozpustí v apyrogénnej vodě na roztok obsahujúci 2 až 2,5 hmotnostných percent bielkovín, pH roztoku sa upraví na hodnotu 5,6 až 5,9 a za stálého miešania přidává sa v malých dávkách chloroform v pomere 5 až 35 ml na 100 ml roztoku albuminu. Vyprecipitované bielkoviny hlavně lipoidného charakteru sa odseparujú a supernatant predstavujúci albumin sa filtruje cez azbestocelulózové filtre a zohrieva 10 až 48 hodin pri teplote 60 °C.The solution can be used in immuno- -bio production of veterinary treatment preparations. The aim of the new solution is a substantial increase of the quality parameters so far produced animal albumin, increased its therapeutic effect and the extension of the indication. Increasing the effect is achieved by being commercially produced animal albumin, which shows relatively high pyretic reactions dissolved in pyrogen-free water for solution containing 2 to 2.5 weight percent the protein is adjusted to pH 5.6 to 5.9 and added with stirring chloroform in small portions 5 to 35 ml per 100 ml albumin solution. The precipitated mainly lipoid protein and the supernatant representing albumin is filtered through asbestocellulose filters and heats for 10 to 48 hours at 60 ° C.
Description
í 54 J Sposob apyrogénnej úpravy zvieracieho albuminu pre veterinárně intravenózne použitie 1 2 Method of pyrogen-free treatment of animal albumin for veterinary intravenous use 1 2
Riešenie možno použiť v imunologicko-biologickej výrobě veterinárnych liečebných prípravkov.The solution can be used in the immunological-biological production of veterinary medicinal products.
Očelom nového riešenie je podstatné zvýšenie kvalitatívnych parametrov doteraz vyrábaného zvieracieho albuminu, zvýšenie jeho liečebného efektu a rozšírenie indikácie.The aim of the new solution is to substantially increase the qualitative parameters of the animal albumin produced so far, to increase its therapeutic effect and to extend the indication.
Zvýšenie účinku sa dosahuje tým, že komerčně vyrábaný zvierací albumin, ktorý vykazuje poměrně vysoké pyretické reakcie sa rozpustí v apyrogénnej vodě na roztok obsahujúci 2 až 2,5 hmotnostných percent bielkovín, pH roztoku sa upraví na hodnotu 5,6 až 5,9 a za stálého miešania přidává sa v malých dávkách chloroform v pomere až 35 ml na 100 ml roztoku albuminu. Vyprecipitované bielkoviny hlavně lipoidného charakteru sa odseparujú a supernatant predstavujúci albumin sa filtruje cez azbestocelulózové filtre a zohrieva 10 až 48 hodin pri teplote 60 °C.An increase in effect is achieved by dissolving commercially available animal albumin, which exhibits relatively high pyretic reactions, in pyrogen-free water to a solution containing 2 to 2.5 weight percent proteins, adjusting the pH of the solution to 5.6 to 5.9, and with stirring, chloroform is added in small portions at a rate of up to 35 ml per 100 ml albumin solution. The precipitated proteins of mainly lipoid character are separated and the supernatant representing albumin is filtered through asbestos cellulose filters and heated at 60 ° C for 10 to 48 hours.
Vynález sa týká sposobu přípravy apyrogenného albuminu pre veterinárně intravenózne použitie.The invention relates to a process for the preparation of pyrogen-free albumin for veterinary intravenous use.
V súčasnom období u nás zvierací albumin připravovaný v priemyselnom měřítku spravidla obsahuje pyrogenné látky, často hraničiace s toxicitou. To sú zrejme důvody, že použitie takéhoto přípravku k intravenóznej aplikácii je vylúčené. Príkladom je aj Biovetou n. p. — Nitra připravovaný 5 % zvierací albumin pod fy označením „PLAZBION — B“, iktorý sa doporučuje aplikovať iba podkožně, vnútrosvalovo alebo intraperitoneálne.At present, animal albumin produced on an industrial scale usually contains pyrogenic substances, often bordering on toxicity. These are obviously reasons that the use of such a preparation for intravenous administration is excluded. Bioveta n. p. - Nitra prepared 5% animal albumin under the name "PLAZBION - B", which is recommended to be administered only subcutaneously, intramuscularly or intraperitoneally.
Příčinou tohto stavu je kontaminovanie východzieho materiálu a následné pomnoženie mikroflóry v priebehu používaných technologických postupov (odběr krve, transport, uskladnenie a technologické spracovanie j.The cause of this condition is contamination of the starting material and subsequent propagation of the microflora during the technological procedures used (blood collection, transport, storage and technological processing).
Medzi doteraz najznámejšie depyrogenizačné postupy plazmatických bielkovín možno zařadit adsorbciu na aktivně uhlie (Howard F., Spooner E. C. R,: Chemistry and Industry 19671946]; AI2O3 (Szeghi G., Torna E., Stanica E., Stoian C., Gartner M. Arch. Roum. de Pathol. Exper. 21/163/1962 J; Budilina J. A., Filimonova A. A., Ciumanov: ŽMEI 30, 89/1959), azbestové filtre (Co Tui F. W., Wright A. M.: Ann. Surgey 116, 412/1942, Zittle C. A., Devlin Η. B., Rodney G., Welche M.: J. Lab. Clin. Med. 40, 75/1945], popřípadě zohrievanie pri teplote 37 °C (Sgouris J. T., Storey R. W., Mc Call Κ. B., Anderson H. D.: Vox Sang. 7, 739/1962).The most well known plasma protein depyrogenation processes to date include adsorption to activated carbon (Howard F., Spooner EC R: Chemistry and Industry 19671946); AI2O3 (Szeghi G., Torna E., Station E., Stoian C., Gartner M. Arch Roum de Pathol Experiment 21/163/1962 J; Budilina JA, Filimonova AA, Ciumanov: ZMEI 30, 89/1959), asbestos filters (Co Tui FW, Wright AM: Ann. Surgey 116, 412/1942 , Zittle CA, Devlin, B., Rodney, G., Welche, M .: J. Lab. Clin. Med. 40, 75/1945], or heating at 37 ° C (Sgouris JT, Storey RW, Mc Call) B., Anderson HD: Vox Sang. 7, 739/1962).
Nevýhoda citovaných depyrogenizačných spůsobov je nedokonalý depyrogenizačný efekt, nereprodukovatefnosť a v niektorých prípadoch dlhý technologický postup.The disadvantage of the cited depyrogenizing processes is the imperfect depyrogenizing effect, non-reproducibility and in some cases a long technological process.
Vyššie uvedené nevýhody odstraňuje riešenie, ktorého podstata spočívá v tom, že komerčně připravený zvierací albumin sa rozpustí v apyrogennej vodě na 2 až 2,5 hmotnostných % bielkovín a za stálého miešania sa upraví jeho pH 1 M kys. octovou na hodnotu 5,6 až 5,9 a za stálého miešania sa přidává chloroform v pomere 5 až 35 mililtrov na 100 ml roztoku. Vzniklá zrazenina predstavujúca balastné bielkoviny hlavně lipoidného charakteru, představuje odpad, ktorý sa centrifugáciu odstráni v podobě sedimentu. Získaný supernatant je roztok albuminu, ktorý sa filtruje cez azbestocelulózové filtre a zohrieva pri teplote 60 °C po dobu 10 až 48 hodin. Keďže ide o určitý purifikačný postup strata na albumine Tabulka 1The above-mentioned disadvantages are overcome by a solution which consists in dissolving commercially produced animal albumin in pyrogen-free water to 2 to 2.5% by weight of proteins and adjusting its pH with 1 M acid with stirring. acetic acid to 5.6-5.9 and chloroform is added at a rate of 5-35 milliliters per 100 mL of solution with stirring. The resulting precipitate, representing ballast proteins of mainly lipoid character, constitutes waste which is removed by centrifugation as sediment. The supernatant obtained is an albumin solution which is filtered through asbestos cellulose filters and heated at 60 ° C for 10 to 48 hours. As this is a certain purification procedure, loss of albumin Table 1
Výrobok Vzostup teplůt na troch králíkoch °C je minimálna, nakolko pokles % bielkovín predstavujú balastné bielkoviny.Product The rise in temperatures in three rabbits ° C is minimal since the decrease in protein% is a ballast protein.
Výhoda navrhovaného postupu je technologická nenáročnost, dostupnost použitých surovin a materiálov a najmá vysoký jednoznačný depyrogenizačný efekt (viď tabulka č. 1).The advantage of the proposed procedure is technological undemanding, availability of used raw materials and materials and especially high unambiguous depyrogenisation effect (see Table 1).
Doterajšia aplikácia pyrogenného zvieracieho albuminu je málo účinná, lebo sa tento může podávat zvieratám iba intramuskulárne. Přitom chorobné stavy zvierat najmá mláďat pri metabolických poruchách zapříčiněných výživou a-ko aj patogenným agnens si vyžadujú doplnenie, resp. stabilizáciu koloidno-osmotického tlaku krvného riečišťa.The application of pyrogenic animal albumin to date is poorly effective, since it can only be administered intramuscularly to animals. At the same time, the disease states of the animals, especially the offspring, in metabolic disorders caused by nutrition, as well as pathogenic agents, require supplementation, respectively. stabilization of colloid-osmotic pressure of the bloodstream.
Příklad 1Example 1
100 g lyofilizovaného albuminu sa rozpustí v 3 500 ml apyrogennej vodě, hodnota pH roztoku sa upraví na 5,6 přidáním 1 M kys. octovej a za stálého miešania k roztoku albuminu po kvapkách sa přidává 575 ml chloroformu. Po dvojhodinovom miešení a 12 hodinovej precipitácii pri teplote + 10 °C vzniklý precipitát sa oddělí centrifugáclou. Supernatant sa filtruje cez čeriace a následné sterilizačné azbestocelulózové vložky. Filtrát sa namrazuje, lyofillzuje, potom rozpúšťa v roztoku stabilizátorov, sterilně filtruje a zohrieva pri 60 °C po dobu 10 hodin.100 g of lyophilized albumin is dissolved in 3500 ml of pyrogen-free water, the pH of the solution is adjusted to 5.6 by adding 1 M acid. acetic acid and 575 ml of chloroform are added dropwise to the albumin solution while stirring. After stirring for 2 hours and precipitation for 12 hours at + 10 ° C, the precipitate formed is separated by centrifugation. The supernatant is filtered through clarifying and subsequent asbestos cellulose sterilization pads. The filtrate is frozen, lyophilized, then dissolved in a stabilizer solution, sterile filtered and heated at 60 ° C for 10 hours.
Příklad 2Example 2
100 g lyofilizovaného albuminu sa rozpustí v 3 500 ml apyrogennej vodě, hodnota pH roztoku sa upraví na 5,9 přidáním 1 M kys. octovej a za stálého miešania k roztoku albuminu po kvapkách sa přidává 450 ml chloroformu. Po dvojhodinovom miešení a 12 hodinovej precipitácii pri teplote + 10 °C vzniklý precipitát sa oddělí centrifugáciou Supernatant sa filtruje cez čeriace a následné sterilizačné azbestocelulózové vložky. Filtrát sa namrazuje, lyofilizuje, potom rozpusta v roztoku stabilizátorov, sterilně filtruje a zahrieva pri 60 °C po dobu 48 hodin. Hodnotenie stupňa depyrogenizácie:100 g of lyophilized albumin is dissolved in 3500 ml of pyrogen-free water, the pH of the solution is adjusted to 5.9 by adding 1 M acid. acetic acid and 450 ml of chloroform are added dropwise to the albumin solution. After stirring for 2 hours and precipitation at + 10 ° C for 12 hours, the precipitate formed is collected by centrifugation. The filtrate is frozen, lyophilized, then dissolved in a stabilizer solution, sterile filtered and heated at 60 ° C for 48 hours. Evaluation of the degree of depyrogenation:
V tabulke č. 1 sú uvedené hodnoty vzostupu teplůt na troch králikoch a priemer týchto hodnůt v °G u východzieho hovádzieho albuminu a hovádzieho albuminu po depyrogenizácii.In table no. 1 shows the temperature rise values in three rabbits and the mean of these values in ° G for the starting bovine albumin and the bovine albumin after depyrogenation.
hotnůt 0 hodnota v °C poklesu v °C0 value in ° C decrease in ° C
Komerčně připravenýCommercially prepared
příkladu 2of Example 2
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS805284A CS248086B1 (en) | 1984-10-23 | 1984-10-23 | Method of apyrogenic treatment of animal alumin for veterinary intravein application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS805284A CS248086B1 (en) | 1984-10-23 | 1984-10-23 | Method of apyrogenic treatment of animal alumin for veterinary intravein application |
Publications (1)
Publication Number | Publication Date |
---|---|
CS248086B1 true CS248086B1 (en) | 1987-01-15 |
Family
ID=5430604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS805284A CS248086B1 (en) | 1984-10-23 | 1984-10-23 | Method of apyrogenic treatment of animal alumin for veterinary intravein application |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS248086B1 (en) |
-
1984
- 1984-10-23 CS CS805284A patent/CS248086B1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0101935B1 (en) | Process for the preparation of the c1 inactivator and its use | |
US6835379B2 (en) | Method of producing IgG | |
JPS5874617A (en) | Method for heat treatment of aqueous solution containing human blood coagulation factor 7 | |
DE68928527T2 (en) | Composition containing albumin and process for its preparation | |
NL7905220A (en) | ANTI-THROMBINE PREPARATION AND METHOD FOR PREPARING IT. | |
EP0037078A2 (en) | Process for heat treatment of aqueous solution containing human blood coagulation factor XIII | |
DE2801123A1 (en) | METHOD FOR PRODUCING AN INTRAVENOUS APPLICABLE SERUM PROTEIN PREPARATION | |
JPS63243032A (en) | Heat treatment method for thrombin | |
JP2012102115A (en) | Albumin-purification method including nanofiltration process, and albumin-containing solution and composition for therapeutical use | |
JPH0261482B2 (en) | ||
EP0271885B1 (en) | Medicine containing the tissular protein pp4, process for the preparation of pp4 and its pasteurization, and the use of pp4 | |
EP0117064B1 (en) | Process for heat treatment of blood coagulation factor viii | |
US4476109A (en) | Method of preparing gamma globulin suitable for intravenous administration | |
DE69733548T2 (en) | CLEANING PROCESS | |
US4285933A (en) | Process for concentrating blood coagulation Factor XIII derived from human placentae | |
CS248086B1 (en) | Method of apyrogenic treatment of animal alumin for veterinary intravein application | |
US3905870A (en) | Purification of kallikrein | |
US3627642A (en) | Lysozyme salts | |
JPS58895A (en) | Method for producing L-tryptophan | |
JPS6160050B2 (en) | ||
DE1517750B1 (en) | Process for obtaining practically albumin-free lysozyme | |
US2432970A (en) | Method of reducing the pyrogen contents of parenteral solutions | |
RU2745443C1 (en) | Method for obtaining agent with antihypoxic, regenerative activity | |
US2830931A (en) | Process of removing colored impurities from heparin | |
SU467536A1 (en) | The method of obtaining serum albumin |